Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594469 | 0.97 | BACE1 (0.41) | BACE1BACE2CTSD | |
| SCHEMBL2594466 | 0.97 | BACE1 (0.41) | BACE1BACE2CTSD | |
| SCHEMBL15471589 | 0.94 | BACE1 (0.42) | BACE1BACE2CTSD | |
| SCHEMBL12937707 | 0.87 | BACE1 (0.39) | BACE1BACE2 | |
| SCHEMBL12272931 | 0.87 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL12272934 | 0.87 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL1975733 | 0.86 | BACE1 (0.42) | BACE1BACE2 | |
| SCHEMBL1975731 | 0.86 | BACE1 (0.42) | BACE1BACE2 | |
| SCHEMBL10321460 | 0.86 | BACE1 (0.38) | BACE1BACE2CTSD | |
| SCHEMBL1173592 | 0.86 | BACE1 (0.38) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877744-B2 | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8748418-B2 | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885CTSD 658/4885 |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885CTSD 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.